

FORM 5

QUARTERLY LISTING STATEMENT

Name of Listed Issuer: VEXT Science Inc. (the "Issuer").

Trading Symbol: VEXT

This Quarterly Listing Statement must be posted on or before the day on which the Issuer's unaudited interim financial statements are to be filed under the *Securities Act*, or, if no interim statements are required to be filed for the quarter, within 60 days of the end of the Issuer's first, second and third fiscal quarters. This statement is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies. If material information became known and was reported during the preceding quarter to which this statement relates, management is encouraged to also make reference in this statement to the material information, the news release date and the posting date on the Exchange website.

General Instructions

- (a) Prepare this Quarterly Listing Statement using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Listed Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

There are three schedules which must be attached to this report as follows:

SCHEDULE A: FINANCIAL STATEMENTS

See attached

SCHEDULE B: SUPPLEMENTARY INFORMATION

The supplementary information set out below must be provided when not included in Schedule A.

1. Related party transactions

Provide disclosure of all transactions with a Related Person, including those previously disclosed on Form 10. Include in the disclosure the following information about the transactions with Related Persons:

- (a) A description of the relationship between the transacting parties. Be as precise as possible in this description of the relationship. Terms such as affiliate, associate or related company without further clarifying details are not sufficient.
- (b) A description of the transaction(s), including those for which no amount has been recorded.
- (c) The recorded amount of the transactions classified by financial statement category.
- (d) The amounts due to or from Related Persons and the terms and conditions relating thereto.
- (e) Contractual obligations with Related Persons, separate from other contractual obligations.
- (f) Contingencies involving Related Persons, separate from other contingencies.

Key management personnel

Key management personnel include those persons having authority and responsibility for planning, directing, and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of members of the Company's Board of Directors and corporate officers, including the Company's, Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, and Corporate Secretary.

Remuneration attributed to key management personnel for the three months ended March 31, 2026 and March 31, 2025 is summarized as follows:

(Expressed in thousands of United States Dollars, except percentages, share, and per share amounts)

	March 31, 2026	March 31, 2025
CEO, COO, and Director	\$ —	\$ —
CFO	1	1
Corporate Secretary	1	—
Director	—	1
Director	—	1
Director	—	1
Director	—	1
Share-based compensation	2	5
CEO, COO, and Director	86	83
CFO	59	50
Corporate Secretary	54	45
Salaries and wages	199	178
Director	34	34
Director	40	21
Director	12	9
Director	12	9
Director	12	9
Consulting fees included in operating expenses	110	82
Total	\$ 311	\$ 265

All key management personnel remuneration are recorded at actual current costs and are paid as part of their ongoing contractual commitment with the Company in the form of an Employment Agreement or a Director Retainer Agreement.

Due from related parties

The current portion of balances due from related parties is as follows:

(Expressed in thousands of United States Dollars, except percentages, share, and per share amounts)

	March 31, 2026	December 31, 2025
Beginning Balance	\$ 1,063	\$ 1,347
Payments	(34)	(440)
Interest Accrued	31	156
11.5% per annum interest bearing, due on December 31, 2026	1,060	1,063
Insurance premiums	9	10
Total due from related party	\$ 1,069	\$ 1,073

On December 31, 2025, the Company and the related party entered into a Consent and Amending Agreement, by which the Company received \$305 in payments and the maturity date of the existing promissory note was amended to the earlier of (x) December 31, 2026, (y) the date in which the related party sells any shares of the Company (subject to limited exceptions), and (z) any change of control of the Company. The Company has recorded a \$9 receivable from a related party representing insurance premiums and related costs paid by the

FORM 5 – QUARTERLY LISTING STATEMENT

January 2015

Page 3

Company on behalf of the related party. These amounts are reimbursable pursuant to the underlying arrangement and are expected to be settled in the ordinary course of business. The balance is non-interest bearing and due on demand unless otherwise specified.

Due to related party:

A Director was one of the sellers of the App Pharma entities and as such holds a portion of the promissory notes payable for App Pharms Products and App Pharms Processing. During the period ended March 31, 2026, \$14 in interest was accrued on these notes payable. Payment of interest began January 1, 2025. During the period ended March 31, 2026 and December 31, 2025, the portion of the promissory notes payable due is as follows:

(Expressed in thousands of United States Dollars, except percentages, share, and per share amounts)

	March 31, 2026	December 31, 2025
Total Current Promissory Note Payable (Director)	\$ 718	\$ 723
Interest Payable	14	14
Total Interest Payable (Director)	\$ 14	\$ 14

2. Summary of securities issued and options granted during the period.

Provide the following information for the period beginning on the date of the last Listing Statement (Form 2A):

(a) summary of securities issued during the period,

Date of Issue	Type of Security (common shares, convertible debentures, etc.)	Type of Issue (private placement, public offering, exercise of warrants, etc.)	Number	Price	Total Proceeds	Type of Consideration (cash, property, etc.)	Describe relationship of Person with Issuer (indicate if Related Person)	Commission Paid
No securities granted during the period								

(b) summary of options granted during the period,

Date	Number	Name of Optionee if Related Person and relationship	Generic description of other Optionees	Exercise Price	Expiry Date	Market Price on date of Grant
No options granted during the period						

3. Summary of securities as at the end of the reporting period.

Provide the following information in tabular format as at the end of the reporting period:

- (a) description of authorized share capital including number of shares for each class, dividend rates on preferred shares and whether or not cumulative, redemption and conversion provisions,

Description	Number Authorized	Par Value
Subordinated Voting Shares	Unlimited	Without Par Value
Multiple Voting Shares *	Unlimited	Without Par Value

** Each multiple voting share can be converted into 100 subordinated voting shares.*

- (b) number and recorded value for shares issued and outstanding,

Description	Number Issued and Outstanding	Value (in thousands of USD)
Subordinated Voting Shares	185,793,173	\$51,602
Multiple Voting Shares *	618,907	\$1,934
Total	186,412,080	\$53,536,000

** Each multiple voting share can be converted into 100 subordinated voting shares.*

- (c) description of options, warrants and convertible securities outstanding, including number or amount, exercise or conversion price and expiry date, and any recorded value, and

Description	Number Outstanding	Exercise Price in CAD	Expiry Date
Stock Options	676,000	\$ 1.00	January 4, 2029
Stock Options	200,000	\$ 1.00	May 13, 2029
Stock Options	833,334	\$ 0.75	May 12, 2030
Stock Options	375,000	\$ 0.75	November 26, 2030

Stock Options	235,000	\$ 1.22	January 6, 2031
Stock Options	500,000	\$ 1.43	February 19, 2031
Stock Options	190,000	\$ 0.58	April 19, 2032
Stock Options	10,000	\$ 0.58	June 23, 2032
Stock Options	1,000,000	\$ 1.00	August 24, 2032
Stock Options	250,000	\$ 0.60	August 24, 2032
Stock Options	125,000	\$ 0.50	December 22, 2032
Stock Options	245,000	\$ 0.50	March 22, 2033
Stock Options	200,000	\$ 0.68	September 11, 2033
Stock Options	884,950	\$ 0.48	May 24, 2034
Stock Options	50,000	\$ 0.49	October 31, 2034
TOTAL:	5,774,284		

Description	Number Outstanding	Exercise Price in CAD	Expiry Date
Restricted Share Unit	100,000	N/A	June 16, 2028

Description	Number Outstanding	Exercise Price in CAD	Expiry Date
Special Advisory Warrants	280,000	\$ 1.00	December 31, 2027

- (d) number of shares in each class of shares subject to escrow or pooling agreements or any other restriction on transfer.

As at December 31, 2025, approximately 1,425,300 subordinated voting shares and 472,921 multiple voting shares beneficially owned by Director Jason T. Nguyen are pledged as security for a promissory note due to the Company. No other escrow or pooling agreements exist.

4. List the names of the directors and officers, with an indication of the position(s) held, as at the date this report is signed and filed.

Name	Position
Eric Offenberger	CEO, COO, President, Director
Trevor Smith	CFO
Mark Opzoomer	Director
Thai Nguyen	Director
Terry Creighton	Director
David Johns	Director
Spiro Phanos	Director
Scott Everett	General Counsel, Corporate Secretary

SCHEDULE C: MANAGEMENT DISCUSSION AND ANALYSIS

See attached

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Quarterly Listing Statement.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated May 26, 2026

Trevor Smith
Name of Director or Senior Officer

"Trevor Smith"
Signature

CFO
Official Capacity

Issuer Details		For Quarter Ended	Date of Report
Name of Issuer		March 31, 2026	YY/MM/DD
Vext Science Inc.			26/05/26
Issuer Address			
4152 N 39 th Ave			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Phoenix, AZ 85019		()	1-844-211-3725
Contact Name		Contact Position	Contact Telephone No.
Trevor Smith		CFO	1-844-211-3725
Contact Email Address		Web Site Address	
Trevor.s@vextscience.com		www.vextscience.com	